Diabetic Wound Care That Delivers in Salem, OR

CDC PLACES vs. JF: two files, not one brochure

Salem is a city under 250k (178,510 Census). CDC PLACES (2023, crude) estimates 11.7% of adults in Salem have diagnosed diabetes — 0.3 points below the U.S. 12% figure. Adult arthritis here is 26.3% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Epidemiology is not a protocol

• CDC PLACES (2023, crude) estimates 11.7% of adults in Salem have diagnosed diabetes — 0.3 points below the U.S. 12% figure. Adult obesity in Salem is 41.4% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. A CTP without offloading and serial measurements still fails JF review. Product is the last step, not the first.
• Joint-preservation biologics compete with cortisone and viscosupplementation pathways that already have familiar CPT habits. The operational gap in Oregon is staff training and consent language, not another brand name on a centrifuge.
• Oregon is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Uninsured mix and Medicare CTPs in the same building

America’s Health Rankings (BRFSS 2024) only publishes state diabetes as a range nationally (Colorado 8.4% to West Virginia 18.4%). For Salem we use CDC PLACES instead of interpolating a fake city rate from that range. CDC PLACES (2023, crude) estimates 11.7% of adults in Salem have diagnosed diabetes — 0.3 points below the U.S. 12% figure.

How we’d stand this up in clinic